NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis, Inc. is based in CARMEL, Ind.
| Revenue (Most Recent Fiscal Year) | $2.69M |
| Net Income (Most Recent Fiscal Year) | $-8.24M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.78 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.89 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -222.87% |
| Net Margin (Trailing 12 Months) | -229.49% |
| Return on Equity (Trailing 12 Months) | -619.23% |
| Return on Assets (Trailing 12 Months) | -184.41% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.82 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.76 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 8.48 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.43 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.99 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 9.86M |
| Free Float | 8.36M |
| Market Capitalization | $25.04M |
| Average Volume (Last 20 Days) | 0.06M |
| Beta (Past 60 Months) | 3.10 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 15.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 11.77% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |